Curative effect of iodine125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage nonsmall cell lung cancer

Abstract

Abstract:ObjectiveTo review the efficacy and safety of combination of iodine125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage nonsmall cell lung cancer (NSCLC). MethodsEightytwo cases of peripheral NSCLC patients were divided into the experimental group (n=32) and the control group (n=50) by different treatment methods. The patients in experimental group were treated by iodine125 brachytherapy combined with concurrent chemoradiotherapy, and the patients in control group were treated by concurrent chemoradiotherapy. The two groups were treated with helical tomotherapy, and the chemotherapy regimen was PC regimen (paclitaxel + cisplatin) or TP regimen (taxotere + cisplatin). The response rate (RR), progression free survival (PFS), overall survival (OS) and adverse reactions were observed. ResultsThe RR of experimental group and control group was 87.5% and 76.0%, and the difference was not statistically significant (χ2=0.992, P=0.319). The median PFS was 16 months and 11 months, and the difference was statistically significant (χ2=5.216, P=0.022). The median OS was 26 months and 19 months, and the difference was not statistically significant (χ2=1.085, P=0.298). There were no statistically significant differences of the occurrence rates of adverse reactions in the experimental group and the control group such as radioactive pneumonia (18.75% vs. 24.00%, χ2=0.314, P=0.575), radiation esophagitis (25.00% vs. 30.00%, χ2=0.242, P=0.623), digestive tract reaction (21.88% vs. 26.00%, χ2=0.180, P=0.671), bone marrow suppression (12.50% vs. 16.00%, χ2=0.014, P=0.907) and hemopneumothorax (6.25% vs. 0, P=0.149). ConclusionThe combination of iodine125 brachytherapy with concurrent chemoradiotherapy is a safe and effective treatment for middle and advanced stage NSCLC, which is worthy of further research and promotion.

Key words:Lung neoplasms,Radiotherapy,Drug therapy,Iodine125 brachytherapy

Sun Ying, Wang Ning, Guo Zhanwen, Yan Ying. Curative effect of iodine125 brachytherapy and concurrent chemoradiotherapy for middle and advanced stage nonsmall cell lung cancer[J]. Journal of International Oncology, 2017, 44(10): 740-744.

References

［1］ Wagner TD, Yang GY. The role of chemotherapy and radiation in the treatment of locally advanced nonsmall cell lung cancer (NSCLC)［J］. Curr Drug Targets, 2010, 11(1): 6773. ［2］ Fleischman EH, Kagan AR, Streeter OE, et al. Iodine125 interstitial brachytherapy in the treatment of carcinoma of the lung［J］. J Surg Oncol, 1992, 49(1): 2528. ［3］ MartínezMonge R, Pagola M, Vivas I, et al. CTguided permanent brachytherapy for patients with medically inoperable earlystage nonsmall cell lung cancer (NSCLC)［J］. Lung Cancer, 2008, 61(2): 209213. DOI: 10.1016/j.lungcan.2007.12.016. ［4］ Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase Ⅲ randomized trial for highrisk operable nonsmallcell lung cancer［J］. J Clin Oncol, 2014, 32(23): 24562462. DOI: 10.1200/JCO.2013.53.4115. ［5］ Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)［J］. Int J Radiat Oncol Biol Phys, 1995, 31(5): 13411346. DOI: 10.1016/03603016(95)00060C. ［6］孙文泽, 宋丽萍, 张莹冰, 等. 93例Ⅲ期非小细胞肺癌同步放化疗加巩固化疗与序贯放化疗的对比研究［J］. 南方医科大学学报, 2012, 32(3): 362367. DOI: CNKI: 441627/R.20120307.1635.018. ［7］ Kim M, Lee J, Ha B, et al. Factors predicting radiation pneumonitis in locally advanced nonsmall cell lung cancer［J］. Radiat Oncol J, 2011, 29(3): 181190. DOI: 10.3857/roj.2011.29.3.181. ［8］ Chen HH, Jia RF, Yu L, et al. Bystander effects induced by continuous lowdoserate 125I seeds potentiate the killing action of irradiation on human lung cancer cells in vitro［J］. Int J Radiat Oncol Biol Phys, 2008, 72(5): 15601566. DOI: 10.1016/j.ijrobp.2008.07.038. ［9］ Guckenberger M, Kavanagh A, Partridge M. Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage Ⅲ nonsmall cell lung cancer［J］. Strahlenther Onkol, 2012, 188(10): 894900.DOI: 10.1007/s0006601201619. ［10］ Wang ZM, Lu J, Liu T, et al. CTguided interstitial brachytherapy of inoperable nonsmall cell lung cancer［J］. Lung Cancer, 2011, 74(2): 253257. DOI: 10.1016/j.lungcan.2011.03.006. ［11］ Chen H, Bao Y, Yu L, et al. Comparison of cellular damage response to lowdoserate 125I seed irradiation and highdoserate gamma irradiation in human lung cancer cells［J］. Brachytherapy, 2012, 11(2): 149156. DOI: 10.1016/j.brachy.2011.05.002. ［12］ Suchorska B, Ruge M, Treuer H, et al. Stereotactic brachytherapy of lowgrade cerebral glioma after tumor resection［J］. Neuro Oncol, 2011, 13(10): 11331142. DOI: 10.1093/neuonc/nor100. ［13］ Huckle A, AIQaisieh B, Bownes P. Methods of verifying the output of the treatment planning system used for high dose rate (HDR) prostate brachytherapy［J］. Radiother Oncol, 2012, 103(2): 261265. DOI: 10.1016/j.radonc.2011.09.022. ［14］蒲德利, 张福君, 廖江荣, 等. 放射性125I粒子联合化疗治疗晚期非小细胞肺癌的临床研究［J］. 当代医学, 2010, 16(23): 450452. DOI: 10.3969/j.issn.10094393.2010.23.021. ［15］张福君, 李传行, 吴沛宏, 等. 125I粒子组织间植入治疗局部晚期肺癌的对比研究［J］. 中华医学杂志, 2007, 87(46): 32723275. ［16］黄德波, 肖宝荣. 局部晚期非小细胞肺癌的同步放化疗［J］. 国际肿瘤学杂志, 2013, 40(10): 755758. DOI: 10.3767/cma.j.issn.1673422X.2013.10.011.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[7]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[8]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[9]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[10]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[11]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[12]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[15]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.